FAM110B

Across TCGA pan-cancer cohorts, FAM110B mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of FAM110B’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where FAM110B mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types FAM110B is over-expressed in tumor, although a few such as CCRCC and LSCC show the opposite, repressed pattern.

CCRCC, LSCC, and PDAC are the cancer types where FAM110B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FAM110B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	All	−0.747	<.001	11	view →
LSCC	All	All	−0.235	.005	6	view →
PDAC	All	All	−0.732	.001	3	view →
HNSC	All	III,IV	−1.100	.042	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

FAM110B–CCRCC

Open the CCRCC breakdown →